Navigation Links
Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
Date:5/27/2008

tive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.migenix.com.

"Jim DeMesa"

James M. DeMesa, M.D.

President & CEO

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, and forward-looking information within the meaning of applicable securities laws in Canada, (collectively referred to as "forward-looking statements"). Statements, other than statements of historical fact, are forward-looking statements and include, without limitation, statements regarding our strategy, future operations, timing and completion of clinical trials, prospects, plans and objectives of management. The words "anticipates", "believes", "budgets", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "projects", "schedule", "should", "will", "would" and similar expressions are often intended to identify forward-looking statements, which include underlying assumptions, although not all forward-looking statements contain these identifying words. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other things contemplated by the forward-looking statements will not occur.

Although our management believes that the expectations represented by such forward-looking statements are reasonable, there is significant risk that the forward-looking statements may not be achieved, and the underlying assumptions thereto will not prove to be accurate. Forward-looking statements in this news rele
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
3. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
8. MIGENIX releases CEO message #22
9. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
11. MIGENIX Appoints Pieter Dorsman to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...  Neurotech Pharmaceuticals, Inc., announced today the first ... 2 clinical trial of NT-503 Encapsulated Cell Therapy ... choroidal neovascularization secondary to age related macular degeneration ... growth factor (VEGF) receptor protein continuously produced by ... proof-of-concept study will evaluate NT-503 ECT as a ...
(Date:9/2/2015)... NESS ZIONA, Israel , September ... BVXV, TASE: BVXV) today announced the intent of the National ... U.S. National Institutes of Health (NIH) within the Department of ... 2 trial to be held in the United ... examine the use of BiondVax,s universal flu vaccine candidate, Multimeric-001 ...
(Date:9/2/2015)... San Diego, CA (PRWEB) , ... September 02, ... ... from troubleshooting faults in manufacturing equipment, to creating professional commercial video content, to ... beautifully detailed views of fascinating events that go by too quickly to process ...
(Date:9/1/2015)... , Sept. 1, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, announced today ... 17 th Annual Global Investment Conference sponsored by ... 8-10, 2015 at The St. Regis Hotel in ... James Sapirstein , Chief Executive Officer, will provide ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... VPHM ) reported today its financial results for ... In 2010, we: Achieved a record $439 ... net sales of Cinryze® (C1 esterase inhibitor [human]); Attained ... growth over the prior year; GAAP net income reached $126 ...
... in German . , They have been used ... now they are making rapid inroads in high performance applications: ... phones and digital cameras. The automotive industry, for instance, has ... using them in driver assistance systems from parking aids ...
... Feb. 23, 2011 Scarguard Labs, LLC, a closely ... and other dermatological problems through the use of multi-technology ... today that they have received approval from Health Canada ... "We are very pleased to gain approval ...
Cached Biology Technology:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 11UV-transparent coating for image sensors 2
(Date:8/5/2015)... 5, 2015 The biosensors market is proving ... penetration into newer sectors, and development of devices resulting ... space has seen the entry of multiple participants each ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... of the Global Biosensors Market ( http://www.frost.com/nee9 ), ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... solutions, today announced that members of the executive management ... Pacific Crest Global Technology Leadership Forum on Tuesday, August ... will be held at the Sonnenalp Resort in ... presentation may include forward-looking information. An audio webcast of ...
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... WASHINGTON, Oct. 9 -- Medical research is a cornerstone ... Meeting of the Optical Society (OSA), being held Oct. ... FiO 2008 will take place alongside Laser Science ... Division of Laser Science. Reporters interested in obtaining ...
... between the promise of victory and the dread of defeat ... in the brain,s architecture, according to a new imaging study. ... identified distinct brain regions with competing responses to risk. ... behind the forehead involved in analysis and planning. ...
... North Carolina State University researchers are launching a new ... throughout the state, decrease the cost of providing the ... hopefully contribute to the establishment of nationwide standards for ... led by Dr. Ann H. Ross, has received a ...
Cached Biology News:Where optics meets medicine 2Where optics meets medicine 3Where optics meets medicine 4Where optics meets medicine 5Where optics meets medicine 6Where optics meets medicine 7Risk and reward compete in brain 2NC State takes lead in crime scene investigation training 2
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Guava has made microcapillary flow cytometry accessible ... experts alike will appreciate the latest addition ... Pluseasy to use, surprising affordable, and very ... system includes such features as absolute cell ...
...
Fingerprinting II Basic software is used for analyzing fingerprint sample types (electrophoretic gels, HPLC and other chromatographic patterns, spectrophotometric and densitometric curves)....
Biology Products: